title: Changes of selected morphotic parameters and blood plasma proteins in blood of divers after a single short-time operational heliox exposure.
abstract: In the Polish Navy, deep-water dives, performed for the needs of the maritime industry, are conducted using our own national technology and trimix as a breathing medium. In this paper are presented the results obtained during a short-time deep-water diving test using the principles of US Navy technology, combined with the use of diving equipment type AF-2 and heliox-type breathing mixture in the open circuit. In the performed examinations changes in clinical parameters were assessed viz.: blood morphology, hematocrit level, concentration of C3c, C4, IgG, IgA, IgM, CRP, concentration of fibrinogen and factor XII level, obtained 30 minutes prior to commencement, immediately after completion, and 24 hours after termination of the exposure. The results thus generated were subjected to a preliminary analysis by the description of trends observed. It was revealed that the diving technology employed did not generate substantial changes in the examined parameters of blood in divers, and the increase of neutrophils, blood platelets and fibrinogen concentration in the blood plasma immediately after diving is of temporary character, being a typical reaction observed during diving.
authors.affiliation: Department of Maritime and Tropical medicine, Military Medical University, Poland.
authors.forename: Romuald
authors.initials: R
authors.lastname: Olszański
authors.forename: Maciej
authors.initials: M
authors.lastname: Konarski
authors.forename: Brunon
authors.initials: B
authors.lastname: Kierznikowicz
mesh_terms: D000328:Adult; D001798:Blood Proteins / Q000187:drug effects*; D002352:Carrier Proteins; D015932:Complement C3c / Q000187:drug effects; D003181:Complement C4 / Q000187:drug effects; D002373:Cyclic AMP Receptor Protein / Q000187:drug effects; D003664:Decompression; D004242:Diving / Q000502:physiology*; D005174:Factor XII / Q000187:drug effects; D005340:Fibrinogen / Q000187:drug effects; D006371:Helium / Q000008:administration & dosage / Q000494:pharmacology*; D006400:Hematocrit; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology* / Q000628:therapy*; D007070:Immunoglobulin A / Q000187:drug effects; D007074:Immunoglobulin G / Q000187:drug effects; D007075:Immunoglobulin M / Q000187:drug effects; D008297:Male; D009326:Naval Medicine; D010100:Oxygen / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D001798:Blood Proteins; D002352:Carrier Proteins; D003181:Complement C4; D002373:Cyclic AMP Receptor Protein; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D006371:Helium; C038949:heliox; D015932:Complement C3c; D005174:Factor XII; D005340:Fibrinogen; D010100:Oxygen